• Search
  • Menu
Gore
  • Contact
  • Home
  • Products
  • Resource Library
  • News & Events
  • About Gore
  • Careers
  • Contact Us
  • Search
  • Resource Library

Validation Guide: GORE Protein Capture Device for Early Clinical Applications, 9.0mL (PROA103)

GORE Protein Capture Device for Early Clinical Applications, 9.0mL (PROA103)

Validation Guides, English

Share: Mail Copy URL Twitter Linked In Facebook

This unique membrane Device offered in 9.0 mL has a capacity of ≥ 360 mg when using 1.25 mg/mL human polyclonal hIgG in phosphate-buffered solution at 30 seconds residence time (SRT).  Request the Validation Guide for complete testing details.

This document is available upon request.

Contact Us

Americas

+1 800 294 4673

+1 410 506 1715

Europe

+49 89 4612 3456

+800 4612 3456

All Other Inquiries

+1 800 294 4673

+1 410 506 1715

Contact by email

Related Products

Pharmaceutical & Biopharmaceutical

  • Affinity chromatography devices

Related Industries

  • Life Sciences
  • Pharmaceutical & Biopharmaceutical Industry

View all Industries

Chromatography News & Events

Event

Join W. L. Gore & Associates for the Live + Virtual Bioprocessing Summit Europe

March 14, 2023 - March 16, 2023

Join W. L. Gore & Associates at BioProcessing Summit Europe, Europe’s Premier Conference to Optimize Your Bioprocesses

Event

Visit GORE at BioProcess International in San Diego

February 27, 2023 - March 2, 2023

Join W. L. Gore & Associates for BioProcess International, the largest BioProcessing event for learning how to accelerate promising biologics, cell & gene therapies towards commercial success.

Press Release

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

Posted December 12, 2022

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the global CDMO’s contract development and manufacturing services. By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes, eliminate column bioburden issues, increase product material yields in the research and development (R&D) stages, and help lower costs for clinical manufacturing.

View All News & Events

  • Privacy Notice
  • Cookie Settings
  • Terms of Use

Copyright 2023 W. L. Gore & Associates, Inc.

Follow us:

  • LinkedIn
  • YouTube
  • Glassdoor
  • California Supply Chain Act / Human Trafficking Statement